Valirx Plc An Exciting Company

ValiRx shares have plummeted in recent weeks as investors have become wary of the company's business model and its potential for long-term growth. In the following update for our investors, we provide a brief overview of our business strategy and goals for the coming months and report on our progress towards our goal of achieving annual revenue of $1.5 billion by the end of 2017. In the following update, our shareholders, investors and management team of our new company Valis Therapeutics, Inc. (NASDAQ: VVIRX), her thoughts on the future of her company and her vision for the future of the company. [Sources: 1, 10]

We are pleased to give you a brief overview of our successful development progress with our two top candidates VAL101 and VAL301. The company is continuing preclinical development of Val301, with a focus on the treatment of endometriosis, and we are in the process of providing additional information on the successful development and progress of the other leading candidate, Val101. VAL 101 is the platform to produce our top candidate as it is proposed to modulate the bcl2 expression involved in many cancers. This peptide structure is inspired by the naturally occurring androgen receptor and is designed to intercept and prevent SRC kinasing, an enzyme involved as a cancer-causing cell growth pathway. [Sources: 0, 1, 5, 7]

This chart was created to show you exactly how it works and what different outcomes might mean for you as a shareholder. [Sources: 3]

The CEO will answer to the board, even if you are a member of the board, and you can probably influence the board's decisions. In one fell swoop, Peterhouse has ensured that the second vote is genuinely for shareholders who want to run the company. The management of the company runs the business, but not you, but the management of the company. Institutional investors own more than 50% of a company, so if your decisions do not match those of other major shareholders, your ownership size is sufficient to change company policy. [Sources: 2, 3]

Why do you think this is in the best interests of shareholders and why do you care? It is a clear indication that shareholders have the say over what the company does and will serve as a vote to bring the resolution back to the vote. [Sources: 3]

When you register to view the webcasts produced by BRR Media as a company, your name, organization and e-mail address are stored and queried and stored in the database. Apart from the registration data collected from the content produced, we do not share any personal data with other companies or individuals who are not associated with us or with other companies or individuals. For more information on how to complain to the ICO and to read our privacy policy, please visit our website. [Sources: 9]

Jenni Maki Jouppila joined Pharmatest in 2016 and has been working as Research Director and Research and Development Director since then. MSc, she graduated from the inter-collegial faculty of biotechnology at the University of Gdansk and completed her studies in biology. She continued her education at Abo Akademi University, where she received her PhD in cell biology in the Department of Life Sciences. The PhD thesis was defended at the Institute of Molecular Biology and Immunology at the University of Helsinki, Finland. [Sources: 8]

Commercial development has been ongoing since the Memorandum of Understanding between ValiRx and an unspecified Japanese pharmaceutical company to develop and commercialize VAL301 was signed. The material transfer agreement, announced on May 1, 2020, will be signed to allow the undisclosed Japanese pharmaceutical company to evaluate VAL301 as a potential future license that takes into account the potential for future licenses. As reported in the 2018 annual financial statements, 800,000 euros were sold on 7 July 2016, 202,000 euros Euro. After the buyer had not paid the balance, the technology returned to Vali Rx. An agreement on the substantial transfer has been announced and a Letter of Intent between the company and parent company Pharmatest has since been announced, but commercial development is ongoing. [Sources: 5]

At the same time as the transaction, the Company acquired all issued share capital of Bioinnovation (ValiRx) from its existing ordinary shares upon issue. If granted, it may be exercised for a period of one year, subject to the approval of shareholders at the company's upcoming annual general meeting. [Sources: 5, 7]

As the pharmaceutical industry increasingly seeks new therapies in oncology, we believe we are entering a new and very exciting phase. We look forward to further technological advances that, together with innovations in the biotechnology sector, will defeat a number of diseases. The future for Valirx and our shareholders is very promising, given our increasingly secure platform and growing confidence in our clinical and commercial development planning. I am pleased that one of our products will soon enter clinical trials. [Sources: 0, 4, 6]

The company's clinical therapeutics continue to demonstrate the potential to address unmet medical needs in oncology, and we are confident that our gene silencing molecule, in combination with other existing medicines, has potential for effective treatment of a wide range of diseases. Our medicine is a combination of two of Valirx's most advanced technologies, its proprietary gene therapy platform and our proprietary drug delivery system. We are proud that our medicine is being used in clinical trials for multiple sclerosis (MS) and multiple myeloma and have achieved positive results, backed up by our track record in developing and commercializing our other medicines. [Sources: 0, 4, 6]

Sources:

[0]: https://pdf.dfcfw.com/pdf/H2_AN201811071237988543_1.html

[1]: https://www.voxmarkets.co.uk/articles/movers-monday-28-september-2020-192c0b

[2]: https://simplywall.st/news/do-institutions-own-valirx-plc-lonval-shares/

[3]: https://www.linkedin.com/pulse/make-mistake-suzy-dilly?articleId=6646753588020342784

[4]: https://www.ceotodaymagazine.com/2018/06/valirx-and-the-future-of-cancer-treatment

[5]: https://uk.advfn.com/stock-market/london/valirx-VAL/share-news/ValiRx-PLC-Final-Results/82765617?nomobile

[6]: https://www.biospace.com/article/releases/valirx-plc-release-half-yearly-report-/

[7]: http://tools.euroland.com/tools/PressReleases/GetPressRelease/?ID=3685404&lang=en-GB&companycode=service

[8]: https://www.pharmatest.com/index.php/news/pharmatest-services-ltd-partners-valirx-plc-geneice-developm/

[9]: https://www.brrmedia.co.uk/company-details/531e633f3665390e1e004495

[10]: https://markets.ft.com/data/announce/full?dockey=1323-14015123-5QUE5BDN5AF871PABQVFISTKNJ